Integrity Alliance LLC. Invests $451,000 in Celcuity, Inc. $CELC

Posted by George Bondi on May 30th, 2026

Integrity Alliance LLC. purchased a new position in Celcuity, Inc. (NASDAQ:CELC – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 4,522 shares of the company’s stock, valued at approximately $451,000.

Several other hedge funds have also recently modified their holdings of CELC. Creative Planning purchased a new stake in shares of Celcuity in the 2nd quarter worth approximately $177,000. Rhumbline Advisers lifted its position in shares of Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after purchasing an additional 503 shares during the period. XTX Topco Ltd purchased a new stake in shares of Celcuity in the 2nd quarter worth approximately $169,000. Quantinno Capital Management LP lifted its position in shares of Celcuity by 20.7% in the 2nd quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock worth $3,245,000 after purchasing an additional 41,756 shares during the period. Finally, Paloma Partners Management Co lifted its position in shares of Celcuity by 285.8% in the 2nd quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock worth $1,097,000 after purchasing an additional 60,849 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Trading Up 1.5%

NASDAQ:CELC opened at $132.88 on Friday. Celcuity, Inc. has a 52 week low of $10.50 and a 52 week high of $151.02. The firm has a 50 day moving average of $123.09 and a 200 day moving average of $110.94. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. The stock has a market capitalization of $6.48 billion, a price-to-earnings ratio of -34.07 and a beta of 0.09.

Celcuity (NASDAQ:CELC – Get Free Report) last posted its earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10. As a group, sell-side analysts anticipate that Celcuity, Inc. will post -3.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Celcuity news, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director owned 65,000 shares in the company, valued at approximately $9,144,200. This represents a 27.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the transaction, the director owned 6,760 shares in the company, valued at $949,509.60. The trade was a 57.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 37,000 shares of company stock valued at $5,111,950 in the last three months. 13.33% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on CELC. HC Wainwright upped their price target on shares of Celcuity from $165.00 to $185.00 and gave the stock a “buy” rating in a research report on Monday, May 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $157.00 price target on shares of Celcuity in a research report on Friday, May 15th. Wolfe Research reaffirmed an “outperform” rating and issued a $110.00 price target on shares of Celcuity in a research report on Thursday, March 12th. Craig Hallum reaffirmed a “buy” rating and issued a $189.00 price target on shares of Celcuity in a research report on Monday, May 4th. Finally, Weiss Ratings cut shares of Celcuity from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 19th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Celcuity has an average rating of “Moderate Buy” and a consensus price target of $150.27.

View Our Latest Research Report on Celcuity

Celcuity Company Profile

(Free Report)

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.